Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent's Anti-Cholesterol Drug Meets Endpoint in Phase III Trial

publication date: Aug 12, 2021

Suzhou Innovent Bio reported its PCSK-9 inhibitor mAb met its primary endpoint in a Phase III trial in China patients with heterozygous familial hypercholesterolemia. After 12 weeks of treatment, IBI306 patients showed significantly lower levels of low-density lipoprotein cholesterol than placebo. Safety profiles were similar to other marketed PCSK-9 inhibitors. Innovent pointed out that the results were the first Phase III trial of a PCSK-9 candidate in China patients. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital